Rhabdomyolysis following initiation of posaconazole use for antifungal prophylaxis in a patient with relapsed acute myeloid leukemia: A case report

Mayur D. Mody; Deepak Ravindranathan; Harpaul S. Gill; Vamsi K. Kota

doi:10.1177/2324709617690747

Rhabdomyolysis following initiation of posaconazole use for antifungal prophylaxis in a patient with relapsed acute myeloid leukemia: A case report

Mayur D. Mody, Deepak Ravindranathan, Harpaul S. Gill, Vamsi K. Kota

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications, posaconazole is known to have many side effects and drug-drug interactions. We present a patient who developed rhabdomyolysis after being started on posaconazole for prophylaxis in the setting of relapsed acute myeloid leukemia.

Original language	English (US)
Journal	Journal of Investigative Medicine High Impact Case Reports
Volume	5
Issue number	1
DOIs	https://doi.org/10.1177/2324709617690747
Publication status	Published - Jan 1 2017
Externally published	Yes

Fingerprint

Keywords

AML
Acute myeloid leukemia
Posaconazole
Rhabdomyolysis

ASJC Scopus subject areas

Epidemiology
Safety, Risk, Reliability and Quality
Safety Research

Cite this

Mody, M. D., Ravindranathan, D., Gill, H. S., & Kota, V. K. (2017). Rhabdomyolysis following initiation of posaconazole use for antifungal prophylaxis in a patient with relapsed acute myeloid leukemia: A case report. Journal of Investigative Medicine High Impact Case Reports, 5(1). https://doi.org/10.1177/2324709617690747

@article{cf6d1f7199c04482995e85fd39218b58,

title = "Rhabdomyolysis following initiation of posaconazole use for antifungal prophylaxis in a patient with relapsed acute myeloid leukemia: A case report",

abstract = "Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications, posaconazole is known to have many side effects and drug-drug interactions. We present a patient who developed rhabdomyolysis after being started on posaconazole for prophylaxis in the setting of relapsed acute myeloid leukemia.",

keywords = "AML, Acute myeloid leukemia, Posaconazole, Rhabdomyolysis",

author = "Mody, {Mayur D.} and Deepak Ravindranathan and Gill, {Harpaul S.} and Kota, {Vamsi K.}",

year = "2017",

month = "1",

day = "1",

doi = "10.1177/2324709617690747",

language = "English (US)",

volume = "5",

journal = "Journal of Investigative Medicine High Impact Case Reports",

issn = "2324-7096",

publisher = "Sage Publications",

number = "1",

}

TY - JOUR

T1 - Rhabdomyolysis following initiation of posaconazole use for antifungal prophylaxis in a patient with relapsed acute myeloid leukemia

T2 - A case report

AU - Mody, Mayur D.

AU - Ravindranathan, Deepak

AU - Gill, Harpaul S.

AU - Kota, Vamsi K.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications, posaconazole is known to have many side effects and drug-drug interactions. We present a patient who developed rhabdomyolysis after being started on posaconazole for prophylaxis in the setting of relapsed acute myeloid leukemia.

AB - Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications, posaconazole is known to have many side effects and drug-drug interactions. We present a patient who developed rhabdomyolysis after being started on posaconazole for prophylaxis in the setting of relapsed acute myeloid leukemia.

KW - AML

KW - Acute myeloid leukemia

KW - Posaconazole

KW - Rhabdomyolysis

UR - http://www.scopus.com/inward/record.url?scp=85055661288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055661288&partnerID=8YFLogxK

U2 - 10.1177/2324709617690747

DO - 10.1177/2324709617690747

M3 - Article

AN - SCOPUS:85055661288

VL - 5

JO - Journal of Investigative Medicine High Impact Case Reports

JF - Journal of Investigative Medicine High Impact Case Reports

SN - 2324-7096

IS - 1

ER -

Access to Document

10.1177/2324709617690747